Tomasz Stępień

Tomasz Stępień

Auto-generated profile, based on publicly available information

Tomasz Stępień

Department of Endocrine, General and Vascular Surgery Medical University of Lodz, Poland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Thyroid Research
Verified
Journal Article
Open access
PDF file
HPHanna Pisarek
Hanna Pisarek
TSTomasz Stępień
Tomasz Stępień
RKRobert Kubiak
Robert Kubiak
EBEdyta Borkowska
Edyta Borkowska
MPMarek Pawlikowski
Marek Pawlikowski
Human endocrine tumors often express the somatostatin receptors SSTR 1–5 with different intensity. It has been widely investigated their distribution in pituitary adenomas, brain tumors, adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET). Some of studies also concern the expression of SSTRs in thyroid tumors but they are mainly limited to parafollicular C cells – derived medullary thyroid carcinomas (MTC). Results of SSTR 1–5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used. The aim of this study was to report the presence of all the 5 subtypes of SSTR (including 2A and 2B SSTR isoforms) in some surgically treated human thyroid tumors by means of immunohistochemistry and real-time PCR method and to correlate the results obtained with both techniques. SSTR 1 protein was expressed in 88.8% of investigated cases, SSTR 2A and 2B both in 44.4%, SSTR 3 in 55.5%, SSTR 4 in 11.2% and SSTR 5 in 33.3%. SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. We found positive confirmation of both methods in 88.8% for SSTR 1, 2A, 3 subtypes, in 22.2% for SSTR 4 and in 100% for SSTR 5. It suggests that somatostatin multiligand analogs or selective SSTR 1 agonists may be used in thyroid tumors treatment.

Verified
Journal Article
Open access
PDF file
Magdalena Rudzinska-RadeckaMagdalena Rudzinska-Radecka
Magdalena Rudzinska-Radecka
MMMichal Mikula
Michal Mikula
KAKatarzyna Arczewska
Katarzyna Arczewska
EGEwa L. Gajda
Ewa L. Gajda
SSStanislawa Sabalinska
Stanislawa Sabalinska
BCBARBARA CZARNOCKA
BARBARA CZARNOCKA
It is well known that Prospero homeobox 1 (PROX1) is a crucial regulator of lymphangiogenesis, that reprograms blood endothelial cells to lymphatic phenotype. However, the role of PROX1 in tumor progression, especially in angiogenesis remains controversial. Herein, we studied the role of PROX1 in angiogenesis in cell lines derived from follicular thyroid cancer (FTC: FTC-133) and squamous cell carcinoma of the thyroid gland (SCT: CGTH-W-1) upon PROX1 knockdown. The genes involved in angiogenesis were selected by RNA-seq, and the impact of PROX1 on vascularization potential was investigated using human umbilical vein endothelial cells (HUVECs) cultured in conditioned medium collected from FTC- or SCT-derived cancer cell lines after PROX1 silencing. The angiogenic phenotype was examined in connection with the analysis of focal adhesion and correlated with fibroblast growth factor 2 (FGF2) levels. Additionally, the expression of selected genes involved in angiogenesis was detected in human FTC tissues. As a result, we demonstrated that PROX1 knockdown resulted in upregulation of factors associated with vascularization, such as metalloproteinases (MMP1 and 3), FGF2, vascular endothelial growth factors C (VEGFC), BAI1 associated protein 2 (BAIAP2), nudix hydrolase 6 (NUDT6), angiopoietin 1 (ANGPT1), and vascular endothelial growth factor receptor 2 (KDR). The observed molecular changes resulted in the enhanced formation of capillary-like structures by HUVECs and upregulated focal adhesion in FTC-133 and CGTH-W-1 cells. The signature of selected angiogenic genes’ expression in a series of FTC specimens varied depending on the case. Interestingly, PROX1 and FGF2 showed opposing expression levels in FTC tissues and seven thyroid tumor-derived cell lines. In summary, our data revealed that PROX1 is involved in the spreading of thyroid cancer cells by regulation of angiogenesis.

1 April 2003 in Life Sciences
Verified
Journal Article
Closed access
ASAgnieszka Siejka
Agnieszka Siejka
HLHanna Lawnicka
Hanna Lawnicka
JKJan Komorowski
Jan Komorowski
ASAndrew V. Schally
Andrew V. Schally
TST. Stępień
T. Stępień
Henryk StepienHenryk Stepien
Henryk Stepien

Verified
Journal Article
Open access
PDF file
Magdalena Rudzinska-RadeckaMagdalena Rudzinska-Radecka
Magdalena Rudzinska-Radecka
MGMałgorzata Grzanka
Małgorzata Grzanka
ASAnna Stachurska-Skrodzka
Anna Stachurska-Skrodzka
MMMichal Mikula
Michal Mikula
KPKatarzyna Paczkowska
Katarzyna Paczkowska
BCBARBARA CZARNOCKA
BARBARA CZARNOCKA
The prospero homeobox 1 (PROX1) transcription factor is a product of one of the lymphangiogenesis master genes. It has also been suggested to play a role in carcinogenesis, although its precise role in tumour development and metastasis remains unclear. The aim of this study was to gain more knowledge on the PROX1 function in thyroid tumorigenesis. Follicular thyroid cancer-derived cells—CGTH-W-1—were transfected with PROX1-siRNA (small interfering RNA) and their proliferation, cell cycle, apoptosis and motility were then analysed. The transcriptional signature of PROX1 depletion was determined using RNA-Sequencing (RNA-Seq) and the expression of relevant genes was further validated using reverse transcriptase quantitative PCR (RT-qPCR), Western blot and immunocytochemistry. PROX1 depletion resulted in a decreased cell motility, with both migratory and invasive potential being significantly reduced. The cell morphology was also affected, while the other studied cancer-related cell characteristics were not significantly altered. RNA-seq analysis revealed significant changes in the expression of transcripts encoding genes involved in both motility and cytoskeleton organization. Our transcriptional analysis of PROX1-depleted follicular thyroid carcinoma cells followed by functional and phenotypical analyses provide, for the first time, evidence that PROX1 plays an important role in the metastasis of thyroid cancer cells by regulating genes involved in focal adhesion and cytoskeleton organization in tumour cells.

1 September 2025 in Polish Journal of Surgery
Verified
Journal Article
Closed access
EMEwa Machała
Ewa Machała
TSTomasz Aleksander Stępień
Tomasz Aleksander Stępień
KKKrzysztof Kołomecki
Krzysztof Kołomecki
MKMichał Kusiński
Michał Kusiński
Introduction: The analysis of exercise tolerance and physical capacity plays a crucial role in the assessment of recovery and rehabilitation after surgery.Aim: The aim of the study was to assess physical capacity, exercise tolerance prior to and on day 2 after adrenalectomy on the basis of the six-minute walk test (6MWT) and Borg scale.Material and methods: The cohort study included 100 patients with adrenal tumors divided into the study group (SG,n = 50) and control group (CG, n = 50) who underwent adrenalectomy. SG patients met the criterion of inclusion: coexistingcardiovascular, respiratory, or other chronic diseases. The inclusion criteria for CG were the absence of other chronic systemiccomorbidities, age < 65 years. The 6MWT distance and Borg scale ratings (performed the day prior to and on the secondday after surgery) were analyzed according to the age, sex, comorbidities, adrenal and tumor size, hormonal type of adrenaldisease, type of surgery, and occurrence of postoperative complications.Results: Patients from SG covered significantly shorter distances (487.76 46.72 m in SG and 539.82 17.59 m in CG; p<0.001) anddemonstrated a higher level of exertion (p<0.001) before adrenalectomy and more often discontinued 6MWT after surgeries(p = 0.001) compared to CG. The authors confirmed a significant negative correlation between the age of the patients and sixminute walk distance (6MWD) before the operation in the study (rs = –0.40, p = 0.004) and control (rs = –0.74, p<0.001) groups.A significant decrease in the postoperative 6MWT distance (SG: to 231.35 4192 m, CG: to 236.82 54.10 m) and increasedintensity of dyspnea and fatigue according to the Borg scale were confirmed. SG patients were significantly more likely todevelop postoperative complications (p = 0.002).Conclusions: 6MWT is a useful tool to demonstrate physical capacity in patients before and after adrenalectomy. Patients with comorbidities more frequently discontinued 6MWT after surgery and had lower tolerance of physical effort compared to CG patients before and after surgery.